A patient with refractory high-grade B-cell lymphoma and rapid progression under CAR-T-cell therapy was successfully salvaged with inotuzumab- ozogamicin

Leuk Lymphoma. 2022 Sep;63(9):2260-2262. doi: 10.1080/10428194.2022.2074991. Epub 2022 May 20.

Authors

T Strüßmann¹, R Wäsch¹, F Scherer^{1

2}, J A Mutter^{1

3}, D Pfeifer¹, I Bartsch¹, S Giesler¹, G Graziani¹, J Duyster¹, J Finke¹, R Marks¹

Affiliations

¹ Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
² German Cancer Consortium (DKTK) partner site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
³ Faculty of Biology, University of Freiburg, Freiburg, Germany.

PMID: 35593017
DOI: 10.1080/10428194.2022.2074991

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Cell- and Tissue-Based Therapy
Humans
Inotuzumab Ozogamicin
Lymphoma, Large B-Cell, Diffuse*
Receptors, Chimeric Antigen*
Sialic Acid Binding Ig-like Lectin 2

Substances

Receptors, Chimeric Antigen
Sialic Acid Binding Ig-like Lectin 2
Inotuzumab Ozogamicin